In an open clinical study the efficacy and tolerability of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetoxy]
acetic acid (
acemetacin, TV 1322,
Rantudil) were studied in 15 patients (2 female and 13 male) suffering from acute
arthritis urica. Basing on the heterogeneity of the patients it was possible to estimate the minimal dose of
acemetacin necessary to treat slight, moderately severe and extremely severe forms of the complaint. With the exception of one patient who suffered from an extremely severe attack of
gout, all patients were completely free from
pain within 7 days of
therapy. The same results were also valid for the parameters reddening, swelling and functional and impairment. In 12 of 15 cases the assessment of
therapy was given as "good" by the patients as well as the physicians. In only one instance was it necessary to give colchizin concomitantly to ensure that the patient was free from
pain. In this case, the
gout, had over many years, assumed a chronic character and during acute attacks manifested to an almost generalised
arthritis. Despite the relatively high daily doses--in some cases up to 600 mg/day--only one case of slight gastric disorder was recorded as an undesired side effect. This, however, did not necessitate withdrawing the
drug. It can thus be concluded that
acemetacin in the doses used in this study is effective in the
therapy of acute
gout and is well tolerated at relatively high daily doses.